| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 0.1 | 0.1 | 0.0 |
| Other income | 0.0 | 0.1 | 0.0 |
| Total income | 0.1 | 0.2 | 0.0 |
| Profit before exceptional items & tax | -0.4 | -0.5 | -0.4 |
| Profit before tax | -0.4 | -0.5 | -0.4 |
| Net profit | -0.4 | -0.5 | -0.4 |
| Operating margin | -400.0% | -250.0% | 0.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Operating profit, quarter on quarter | +33.30% |
|---|
BSE results filing, NSE: TRABI. Figures extracted from the filing.
Transgene Biotek Ltd: key numbers
- Share price
- ₹2.60
- Market cap
- ₹19.70 Cr
- Revenue (annual)
- ₹0.21 Cr
- Net profit (annual)
- ₹-1.65 Cr
- P/E (TTM)
- -12.2×Sector 57.8×
- Promoter holding
- 23.64%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Transgene Biotek Ltd
All →Transgene Biotek Annual General Meeting
Transgene Biotek has received ROC approval to extend its 36th AGM deadline by three months. The meeting for FY2025-26 will now be held by December 31, 2026.
Transgene Biotek Management Change
Transgene Biotek Ltd announced the resignation of M/s Vasavi & Co. as Statutory Auditors, effective immediately. The auditors cited pre-occupation with other assignments as the reason.
Transgene Biotek Q4 FY26 Results: Net Loss of ₹0.5 Cr, Loss Narrows
Transgene Biotek Ltd reported revenue from operations of ₹0.1 Cr (+0.0% YoY) and a net loss of ₹0.5 Cr for Q4 FY26.
- Key figure
- Net loss ₹0.5 Cr